EVERSANA and Lyfegen Form Strategic Alliance to Transform Global Drug Pricing and Access
核心洞察
EVERSANA (搜索)'s NAVLIN platform, covering 100+ countries and 50+ HTA organizations, joins forces with Lyfegen (搜索)'s Public Drug Agreement Library containing over 7,000 pricing agreements to create a comprehensive market access solution.
The partnership leverages artificial intelligence analytics to help pharmaceutical companies optimize pricing strategies, streamline HTA submissions, and accelerate patient access to essential medications.
This collaboration aims to address healthcare inefficiencies and improve global patient access to medicines by enabling more informed and efficient decision-making in drug pricing and market access.
In a significant move to reshape the pharmaceutical pricing and market access landscape, Switzerland-based Lyfegen (搜索) and US-based EVERSANA (搜索) have announced a strategic partnership that combines their extensive data resources and technological capabilities.
The collaboration merges EVERSANA (搜索)'s NAVLIN platform, a comprehensive global pricing and market access intelligence system, with Lyfegen (搜索)'s Public Drug Agreement Library, the world's largest digital repository of innovative pricing models and public drug pricing agreements. This integration creates a powerful resource for pharmaceutical companies navigating complex market access challenges.
Comprehensive Data Integration
The combined platform leverages data from more than 100 countries and insights from over 50 health technology assessment (HTA) organizations through NAVLIN, complemented by Lyfegen (搜索)'s extensive collection of over 7,000 public pricing agreements. This vast dataset provides pharmaceutical companies with unprecedented access to market intelligence and pricing strategies.
AI-Powered Decision Support
The partnership introduces advanced artificial intelligence analytics to transform raw data into actionable insights. This technological enhancement enables pharmaceutical companies to:
- Develop market-specific pricing agreements
- Optimize HTA submissions
- Reduce time spent in administrative processes
- Respond rapidly to market dynamics and regulatory changes
Impact on Healthcare Access
The initiative directly addresses one of healthcare's most pressing challenges: ensuring timely patient access to essential medicines. Jim Lang, EVERSANA (搜索)'s Chief Executive Officer, emphasized this point: "Together with Lyfegen (搜索), we can harness the power of AI to address one of the biggest challenges in healthcare – helping patients get timely access to life-saving medicines."
Streamlined Market Access Process
A key benefit of the platform is its ability to strengthen HTA submissions by providing comprehensive data on clinical effectiveness, cost-effectiveness, and healthcare budget impacts. This streamlined approach aims to reduce the traditional bureaucratic hurdles that often delay drug accessibility.
Future Outlook
Girisha Fernando, CEO of Lyfegen (搜索), described the partnership as a "giant step" toward creating a more sustainable and equitable healthcare environment. The collaboration focuses on building a foundation for a more efficient drug access and pricing landscape, potentially revolutionizing how pharmaceutical companies approach market access strategies.
The partnership represents a significant advancement in addressing global healthcare inefficiencies, with the potential to accelerate patient access to vital therapies while helping pharmaceutical companies navigate an increasingly complex market access environment.